PharmGKB summary: Very important pharmacogene information for angiotensin-converting enzyme

Pharmacogenetics and Genomics

Volumn 20, Issue 2, 2010, Pages 143-146

  Thorn, Caroline F ^a   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACE:insertion deletion; Angiotensin converting enzyme inhibitors; Antihypertensives; Pharmacogenomic; PharmGKB

Indexed keywords

AMLODIPINE; ATENOLOL; BENAZEPRIL; CANDESARTAN; CAPSAICIN; CHLORTALIDONE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; METOPROLOL; NEUROLEPTIC AGENT; PRAVASTATIN;

CORONARY ARTERY DISEASE; DRUG RESPONSE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; INDEL MUTATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY;

ANTIHYPERTENSIVE AGENTS; HUMANS; INDEL MUTATION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS;

EID: 75649088885     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283339bf3     Document Type: Short Survey

References (48)

1. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23:177-183.
2. Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 2003; 35:792-801.
3. Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des 2007; 13:1191-1198.
4. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005; 21:733-740.
5. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006; 98:1123-1133.
6. Kitsios G, Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet 2009; 10:50.
7. Rudnicki M, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009; 10:463-476.
8. Rosskopf D, Michel MC. Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol Rev 2008; 60:513-535.
9. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol 2007; 6:373-378.
10. Rieder MJ, Taylor SL, Clark AG. Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22:59-62.
11. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
12. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17-23.
13. Johnson AD, Gong Y, Wang D, Langaee TY, Shin J, Cooper-Dehoff RM, et al. Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther 2009; 85:36-44.
14. Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med 2008; 86:685-690.
15. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99:2375-2385.
16. Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx FH, Verdouw PD, et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol 1992; 263:H429-H437.
17. Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003; 421:551-554.
18. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332:1177-1181.
19. Lennestal R, Otterblad Olausson P, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615-625.
20. Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf 2006; 29:397-419.
21. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003; 42:297-303.
22. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996; 27:62-66.
23. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994; 90:2199-2202.
24. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58:1268-1278.
25. Huang S, Chen XH, Payne JR, Pennell DJ, Gohlke P, Smith MJ, et al. Haplotype of growth hormone and angiotensin I-converting enzyme genes, serum angiotensin I-converting enzyme and ventricular growth: pathway inference in pharmacogenetics. Pharmacogenet Genomics 2007; 17:291-294.
26. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18:240-252.
27. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111:3374-3383.
28. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
29. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies. J Hypertens 1996; 14:1403-1408.
30. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106:544-549.
31. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-955.
32. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?-A systematic review. Curr Control Trials Cardiovasc Med 2005; 6:16.
33. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. EURODIAB controlled trial of Lisinopril in IDDM. Diabetes 1998; 47:1507-1511.
34. Ha SK, Yong Lee S, Su Park H, Ho Shin J, Jung Kim S, Hun Kim D, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000; 15:1617-1623.
35. Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001; 95:130-135.
36. Zee RY, Rao VS, Paster RZ, Sweet CS, Lindpaintner K. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension 1998; 31:925-928.
37. Yu Y, Niu T, Venners SA, Zhang Y, Chen C, Huang A, et al. Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. Clin Exp Hypertens 2005; 27:83-94.
38. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787.
39. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445:151-152.
40. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
41. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-262.
42. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-1723.
43. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
44. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moye LA, Pfeffer MA, Sacks FM, et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88:347-352.
45. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000; 35:89-95.
46. Van Geel PP, Pinto YM, Zwinderman AH, Henning RH, van Boven AJ, Jukema JW, et al. Increased risk for ischaemic events is related to combined RAS polymorphism. Heart 2001; 85:458-462.
47. Bosse Y, Vohl MC, Dumont M, Brochu M, Bergeron J, Despres JP, et al. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet 2002; 62:45-52.
48. Illi A, Kampman O, Anttila S, Roivas M, Mattila KM, Lehtimaki T, et al. Interaction between angiotensin-converting enzyme and catechol-O- methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 2003; 13:147-151.